Original Article

Ferredoxin Gene Mutation and Metronidazole Susceptibility in Trichomonas vaginalis Isolates from Hamadan, Iran

Abstract

Background: Trichomoniasis is a sexually transmitted infection primarily treated with nitroimidazoles. Driven by increasing concerns about drug resistance, this study evaluated ferredoxin gene mutation and metronidazole susceptibility in Trichomonas vaginalis isolates from Hamedan, Iran.
Methods: This study had two components in Hamadan, 2023: a prevalence assessment of 406 specimens and a laboratory-based analysis of 27 T. vaginalis isolates (one fresh isolate from current sampling and 26 archival isolates from earlier studies). Parasites were cultured and subjected to in vitro metronidazole susceptibility testing. Molecular analyses were performed to detect the -239A>T mutation in the ferredoxin gene promoter using genomic DNA extracted from parasite cultures.
Results: T. vaginalis was identified in only 0.25% (1/406) of clinical specimens through conventional parasitological methods. All isolates were susceptible to metronidazole. Aerobic MLCs significantly decreased from 27.54 ± 22.13 μg/mL at 24 h to 9.12 ± 6.05 μg/mL at 48 h (P<0.001). Of 27 sequenced amplicons, 23 yielded high-quality sequences. One isolate (4.35%) harbored the -239A>T mutation, exhibiting MLCs of 12.5 μg/mL at 24 h and 1.3 μg/mL at 48 h.
Conclusion: Ferredoxin gene mutations showed a low frequency in this region. All isolates, including the sole isolate harboring the −239A>T mutation, were phenotypically susceptible to metronidazole. While these findings cannot definitively rule out the potential role of this mutation in drug resistance, they support the multifactorial nature of metronidazole resistance in T. vaginalis. Consequently, despite the current low prevalence of the infection, ongoing surveillance remains essential to detect emerging resistance and guide clinical management.

1. World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021: accountability for the global health sector strategies 2016–2021. Geneva: World Health Organization; 2021. Web Annex 1: Key data at a glance. Global and regional estimates of four sexually transmitted infections, 2020. Available from: https://iris.who.int/bitstream/handle/10665/342808/9789240030985-eng.pdf
2. Kissinger PJ, Gaydos CA, Seña AC, et al. Diagnosis and Management of Trichomonas vaginalis: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines. Clin Infect Dis. 2022; 13;74(Suppl_2):S152-S161.
3. Van Gerwen OT, Opsteen SA, Graves KJ, et al. Trichomoniasis. Infect Dis Clin North Am. 2023; 37(2):245-265.
4. Muzny CA, Van Gerwen OT, Legendre D. Secnidazole: a treatment for trichomoniasis in adolescents and adults. Expert Rev Anti Infect Ther. 2022; 20(8):1067-1076.
5. Graves KJ, Novak J, Secor WE, et al. A systematic review of the literature on mechanisms of 5-nitroimidazole resistance in Trichomonas vaginalis. Parasitology. 2020; 147(13):1383-1391.
6. Marques-Silva M, Lisboa C, Gomes N, et al.. Trichomonas vaginalis and growing concern over drug resistance: a systematic review. J Eur Acad Dermatol Venereol. 2021; 35(10):2007-2021.
7. Matini M, Maghsood AH, Mohebali M, et al. In Vitro Susceptibility of Iranian Isolates of Trichomonas vaginalis to Metronidazole. Iran J Parasitol. 2016; 11(1):46-51.
8. Leitsch D. A review on metronidazole: an old warhorse in antimicrobial chemotherapy. Parasitology. 2019; 146(9):1167-1178.
9. Huang PJ, Huang CY, Li YX, et al. Dissecting the Transcriptomes of Multiple Metronidazole-Resistant and Sensit-ive Trichomonas vaginalis Strains Identified Distinct Genes and Pathways Associated with Drug Resistance and Cell Death. Biomedicines. 2021; 9(12):1817.
10. Bradic M, Warring SD, Tooley GE, et al. Genetic Indicators of Drug Resistance in the Highly Repetitive Genome of Trichomonas vaginalis. Genome Biol Evol. 2017; 9(6):1658-1672.
11. Xie Y, Zhong P, Guan W, et al. Transcriptional profile of Trichomonas vaginalis in response to metronidazole. BMC Genomics. 2023; 24(1):318.
12. Quon DV, d'Oliveira CE, Johnson PJ. Reduced transcription of the ferredoxin gene in metronidazole-resistant Trichomonas vaginalis. Proc Natl Acad Sci U S A. 1992; 89(10):4402-6.
13. Heidari S, Bandehpour M, Seyyed-Tabaei SJ, et al. Ferredoxin Gene Mutation in Iranian Trichomonas vaginalis Isolates. Iran J Parasitol. 2013; 8(3):402-7.
14. Matini M, Rezaei H, Fallah M, et al. Genotyping, Drug Susceptibility and Prevalence Survey of Trichomonas vaginalis among Women Attending Gynecol-ogy Clinics in Hamadan, Western Iran, in 2014-2015. Iran J Parasitol. 2017; 12(1):29-37.
15. Akbari Z, Matini M. The Study of Trichomoniasis in Pregnant Women Attending Hamadan City Health Centers in 2015. Avicenna J Clin Microbiol Infect. 2017; 4(2):e41533.
16. Morshedloo L, Fallah M, Maghsood AH, et al. Study of Trichomonas vaginalis Infe-ction in Women Visiting Health Centers in Bahar City and Determination of Metronidazole Susceptibility of the Isolated Parasites. Avicenna J Clin Med. 2018; 24(4): 315-321.
17. Azimi Kohn A, Foroughi-Parvar F, Matini S, et al. Prevalence of trichomoniasis in women attending health centers in Asadabad city, West of Iran, during 2021-2022. Avicenna J Clin Microbiol Infect. 2024; 11(1):1-4.
18. Centers for Disease Control and Prevention. Trichomonas vaginalis Susceptibility Testing. Atlanta: CDC; (cited 2026 Sep 4). Available from: https://www.cdc.gov/parasites/hcp/laboratories/trichomonas-vaginalis-susceptibility-testing.html
19. Schwebke JR, Barrientes FJ. Prevalence of Trichomonas vaginalis isolates with resistance to metronidazole and tinidazole. Antimicrob Agents Chemother. 2006; 50(12):4209-10.
20. Karami F, Dastan D, Fallah M, et al. In vitro antitrichomonal activity of Satureja khuzestanica and main essential oil components carvacrol, thymol, and eugenol. J Infect Dev Ctries. 2023; 17(1):80-85.
21. Peebles K, Velloza J, Balkus JE, et al. High Global Burden and Costs of Bacterial Vaginosis: A Systematic Review and Meta-Analysis. Sex Transm Dis. 2019; 46(5):304-311.
22. Salehi M, Minooeianhaghighi M, Mohammadzadeh A, et al. Prevalence and Factors Related to Trichomoniasis, Candidal Vaginitis, and Bacterial Vaginosis in Northeast Iran. Int J Microbiol. 2025; 2025:9573665.
23. Hezarjaribi HZ, Fakhar M, Shokri A, et al. Trichomonas vaginalis infection among Iranian general population of women: a systematic review and meta-analysis. Parasitol Res. 2015; 114(4):1291-300.
24. Moghadamizad Z, Khalili JY, Olfatifar M, et al. The prevalence of Trichomonas vaginalis infection among the female population of Iran: a systematic review and meta-analysis. Int Health. 2024; 16(3):240-251.
25. Matini M, Rezaie S, Mohebali M, et al. Prevalence of Trichomonas vaginalis Infection in Hamadan City, Western Iran. Iran J Parasitol. 2012;7(2):67-72.
26. Kissinger PJ, Gaydos CA, Seña AC, et al. Diagnosis and Management of Trichomonas vaginalis: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines. Clin Infect Dis. 2022; 74(Suppl_2):S152-S161.
27. Upcroft JA, Dunn LA, Wal T, et al. Metronidazole resistance in Trichomonas vaginalis from highland women in Papua New Guinea. Sex Health. 2009; 6(4):334-338.
28. Leitsch D. Recent advances in the molecular biology of the protist parasite Trichomonas vaginalis. Fac Rev. 2021; 10:26.
29. Vidakovic M, Crossnoe CR, Neidre C, et al. Reactivity of reduced [2Fe-2S] ferredoxins parallels host susceptibility to nitroimidazoles. Antimicrob Agents Chemother. 2003; 47(1):302-8.
30. Land KM, Delgadillo-Correa MG, Tachezy J, et al. Targeted gene replacement of a ferredoxin gene in Trichomonas vaginalis does not lead to metronidazole resistance. Mol Microbiol. 2004; 51(1):115-22.
31. Mayr AL, Paunkov A, Hummel K, et al. Comparative proteomic analysis of metronidazole-sensitive and resistant Trichomonas vaginalis suggests a novel mode of metronidazole action and resistance. Int J Parasitol Drugs Drug Resist. 2024; 26:100566.
32. Fallah M, Mosayebi M, Matini M, et al. Prevalence of Trichomoniasis and Determination of in Vitro Susceptibility of Isolated Parasites to Metronidazole in Women Referred to Health Centers in Arak, Iran, in 2020. Avicenna J Clin Med. 2021; 28(3):186-193.
Files
IssueVol 21 No 4 (2026) QRcode
SectionOriginal Article(s)
Keywords
Drug resistance Ferredoxins Iran Metronidazole Microbial sensitivity tests Trichomonas vaginalis

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Karami K, Fallah M, Haghi M, Matini M. Ferredoxin Gene Mutation and Metronidazole Susceptibility in Trichomonas vaginalis Isolates from Hamadan, Iran. Iran J Parasitol. 2026;21(4):478-487.